Background; Anti oestrogenic treatment is widely used for breast cancer treatment and prevention of recurrence. Because of concomitant estrogenic effects, tamoxifen exerts carcinogenic properties on the endometrium. Although secondary endometrial cancers usually present as pure adenocarcinomas, other types of rare tumors have also been reported.
Introduction
Tamoxifen has been widely used during the past two decades in breast cancer for treatment of metastatic disease and for prevention of recurrence after primary treatment. Its anti-tumor effectiveness is mediated by antiestrogen effects. Tamoxifen-related carcinogenic properties on the endometrium have recently been demonstrated however, most probably due to concomitant estrogenic effects. Secondary endometrial cancers usually present as pure adenocarcinomas. We report herein a case of endometrial mesodermal mixed tumor occurring after long-term tamoxifen therapy.
Case report
A 54-year-old woman was referred to our institution with recently diagnosed breast cancer in July 1984. She had had three normal pregnancies and spontaneous menopause had occurred before diagnosis. No other case of breast and/or ovarian cancer was recorded in her family. Her only past medical history was systemic hypertension treated by clonidine. She was not obese.
She underwent radical right mastectomy including homolateral axillary dissection. Pathological examination revealed an infiltrative galactophoric adenocarcinoma with no evidence of lymph node involvement. High levels of progesterone and estradiol receptors were found in the tumor. Both carcino-embryonic antigen (CEA) and CA 15-3 serum levels were below the upper normal limit. Post-operative treatment consisted of six chemotherapy courses using the CAF regimen (5-FU 500 mg/m 2 , doxorubicin 50 mg/m 2 , cyclophosphamide 500 mg/m 2 ). External irradiation was given to the thoracic wall, internal mammary chain and supraclavicular areas (45 Gy) and to the surgical mastectomy wound and axillary chain (50 y). She was given 20 mg of daily tamoxifen. During five years, annual clinical, radiological and biological examinations were performed with no evidence of recurrence. Tamoxifen treatment was discontinued in October 1989 and annual medical follow-up was discontinued at that time. In June 1994, the patient presented with vaginal bleeding and a uterine tumor was diagnosed. She underwent radical hysterectomy with lymphadenectomy. Pathologic examination revealed endometrial mixed mullerian tumor with myometrial extension. There was no lymph node involvement. Post operative external pelvic irradiation (50 Gy) and high-dose rate brachytherapy (14 Gy) were performed in September and October 1994.
In October 1995, she presented with ascites. Cytological examination of peritoneal fluid revealed the presence of malignant adenocarcinomatous cells which were thought to be of mammary origin. The CEA level was normal while CA 15-3 and CA 125 levels were high, 733 units/ml and 18,093 units/ml respectively. Based on the presumption of breast cancer recurrence, the patient received two courses of the previously-described CAF regimen. One month later, however, cytological examination of the peritoneal fluid was repeated, and the working diagnosis was changed to peritoneal dissemination of a mixed mullerian tumor. Consequently, the chemotherapy regimen was changed. Three courses of the CAP combination (carboplatin: a dose calculated to reach an area under the curve of five, doxorubicin 50 mg/m 2 , cyclophosphamide 500 mg/m 2 ) were administered. Complete disappearance of the clinical signs of ascites ensued and CA 15-3 and CA 125 levels dropped to 215 and 1082 units/ml respectively. Congestive heart failure symptoms occurred in February 1996 and myocardiopathy was diagnosed which was presumably related to the cumulative dose of doxorubicin (550 mg/m 2 ). Five additional courses of the same dosages of carboplatine and cyclophosphamide were given and complete clinical response was maintained. Serological CA 15-3 and CA 125 levels fell to 59 and 147 units/ml respectively. During July and August 1996, a new and progressive increase of CA 15-3 and CA 125 levels occurred. The patient received two courses of continuous infusion ifosfamide (1.2 g/m 2 daily during five days). She responded poorly and died in February 1997.
Discussion
The effectiveness of tamoxifen in reducing breast cancer recurrence and death rates as well as occurence of contralateral tumor has been clearly demonstrated [1, 2] . The high antiproliferative effects of this nonsteroidal antiestrogenic synthetic compound are mainly mediated by competitive binding to tumor cell estrogen receptors. However, tamoxifen also exerts estrogen agonistic properties on the uteri of postmenopausal women [3] . Since 1985 [4] , many case reports have described the occurrence of endometrial carcinomas in women receiving or having received tamoxifen for breast cancer. Evidence of an increased risk for endometrial cancer has been demonstrated by most epidemiological studies of patients with breast cancer as well as several randomized controlled trials [5] . The latency period is usually greater than one year, and the median elapsed time between the start of tamoxifen therapy and the diagnosis of adenocarcinoma of the endometrium is 3.5 years. The risk increases with the duration of tamoxifen treatment (relative risk compared to untreated patients (RR) = 3.5 at 5 years versus 2.3 at 2 years) [6, 7] , the daily dosage (RR at 5 years = 3 at 30 mg versus 6 at 40 mg) [8, 9] and with past history of pelvic irradiation (RR = 7.1 for the combination versus 2.6 for tamoxifen alone and 4.7 for pelvic irradiation alone) [10] . Risk seems to be greater in women treated with tamoxifen while pre-or perimenopausal [11] .
We report here a case of mesodermal mixed tumor of the endometrium occurring after exposure to tamoxifen. In this case, there are several arguments in favor of a relationship between tamoxifen treatment and occurrence of endometrial cancer. The latency period was long (ten years) and tamoxifen treatment had been maintained during five years. Our patient presented only one known predisposing factor to endometrial cancer, hypertension but she had no diabetes or obesity and was not nulliparous. She had no history of endometrial polyps or mucosal hyperplasia, no pelvic irradiation, no tamoxifen dose greater than 20 mg per day.
Some particular aspects of the present case are of specific interest. First of all, the histological type was not a pure adenocarcinoma. Histological examination of the resected uterus showed mesodermal mixed tumor, a tumor that contains both epithelial and several stromal elements, that was recently reviewed by Ali and Wells [12] . A variety of terminologies have been applied to this type of tumor. According to the histological typing of the uterine corpus tumors edited by the World Health Organization (WHO), the mixed epithelial and mesenchymal tumors must be classified as follows [13] . Benign tumors are either adenofibroma or adenomyoma. Malignant tumors are classified as adenosarcoma, when only the stromal component is malignant, carcinofibroma, when only the epithelial component is malignant, and carcinosarcoma, when both components are malignant. Carcinosarcoma, malignant mesodermal mixed tumor and malignant mullerian mixed tumor must be regarded as synonyms. The term carcinosarcoma has generally been reserved for tumors with homologous mixture of carcinomatous and sarcomatous features derived from elements normally present in the mullerian system while mesodermal mixed tumors describe those in which heterogenous elements such as muscle and cartilage can be found. So, it appears helpful to add the word 'homologous' or 'heterologous' to any of those malignant mixed tumors, whatever the precise histological type. Mesodermal mixed tumor is uncommon among endometrial cancers accounting for 8% of malignancies of the corpus uteri [14] . The main risk factors are the same as for endometrial adenocarcinoma, namely diabetes mellitus, obesity, hypertension and nulliparity [15] . The predisposing roles of estrogen dependence and prior exposure of the uterine cavity to radiation remains controversial. Pelvic irradiation might be a risk factor, as observed for sarcomas induced in patients treated for Hodgkin's disease [16] . Definitive diagnosis may be made from uterine curettings [17] , with the help of cervical cytology. Radical hysterectomy and pelvic gland dissection with or without venectomy is the recommended surgical curative procedure. Radiotherapy and/ or chemotherapy alone are always palliative procedures. The benefit of such therapy in an adjuvant setting has not been demonstrated. The five-year survival is around 30%. The most powerful prognostic indicator in such tumors is the depth of myometrial invasion [18] . In the overall population of endometrial cancer patients, most of the reported second endometrial cancers following exposure to tamoxifen are adenocarcinomas. From a retrospective study it appears that they could more frequently present as high grade tumors [19] . Rare histologic endometrial tumor types have also been reported and appear to be more frequent following exposure to tamoxifen with a higher proportion of sarcomas and adenosarcomas [19] [20] [21] [22] [23] . In the International Agency for Research on Cancer monograph, out of 108 second cancers, 13 were mesodermal mixed tumors [6] . Another point of particular note in the report is the long delay after cessation of tamoxifen therapy [6] . This has previously been pointed out in another case report on a mullerian carcinosarcoma of the endometrium [24] and could represent a specific feature of this type of tumor. With our patient, we also had to face the difficulty of distinguishing relapsing breast cancer from relapsing endometrial cancer on the basis of the cytological examination of malignant ascites. Finally, we wish to draw attention to the unusually high chemosensitivity of mixed mullerian tumor in our case.
At the present time, the relative risks of developing cancer of the uterine corpus for five years of tamoxifen is evaluated around three [6, 7] . Specific values for rare histological types have not yet been reported. Case reports such as this one are therefore informative, in particular in the clinical setting. Yet, from a public health point of view and with an objective of routine surveillance and recording late complications of therapy, such as the potential carcinogenicity of specific treatment modalities, the only way to achieve a reasonably exhaustive and clear picture, both in terms of absolute and relative risk, is through systematic registering of events of interest. For the occurrence of second cancers following a first primary cancer, the best source in terms of coverage of the whole population of patients is clearly the population-based cancer registry. While frequent events with a high probability occuring as a result of treatment may be noticed in clinical randomized trials, this latter type of study will not pick up rare events, such as second cancers because the size of the study will often be too limited and similarly intermediate risk will go unnoticed. In addition, it should be noted that the population included in trials are often highly selected, in terms of age, comorbidity, place of treatment and the like whereas in contrast population-based registries cover all patients without any exclusion criteria. The only current limitation to this proposed approach is the fact that only few countries have a national coverage by cancer registry or at least coverage of a substantial proportion of the total population. Complementary promising approaches include the Cochrane cancer network. More and more knowledge will be gained from the sharing of information and most importantly this will lead to better care for the patients.
Conclusion
Mesodermal mixed tumors, an uncommon histological type among endometrial tumors, may occur after tamoxifen treatment. The reported higher frequency among secondary endometrial cancers than spontaneous ones supports the causal role of tamoxifen. The failure of our patient to respond to doxorubicin and cyclophosphamide when combined into 5-FU, but the dramatic complete remission when the same two drugs at identical doses were combined with carboplatin emphasizes the primacy platinum in this patient with mullerian carcinoma. The latency period might be longer than for adenocarcinomas and this could justify a long clinical and ultrasonographic follow-up of patients during and after tamoxifen treatment.
